Although not originally part of our research plan, we also made important discoveries about the NLRP3 inflammasome, another key player in the body's defense against infection and control of inflammation. Our findings indicate that the NLRP3 inflammasome requires two steps to become fully operational: first, it is primed to be activated, and then it is activated to trigger a signaling response. Specifically, we discovered that a protein kinase called IKKβ, which is activated during the priming step, helps NLRP3 move to the Golgi apparatus, a special compartment of the cell where NLRP3 can be activated more quickly. Interestingly, another protein called NEK7, previously thought to be essential for this process, was found to be redundant when IKKβ was able to perform its function effectively. This newly identified pathway, observed in human immune cells, appears to be a primary means by which human immune cells use NLRP3 to respond to threats. This suggests that the way NLRP3 prepares to defend the body is more flexible than previously thought.
In the next funding period, we expect significant progress in the molecular characterization of the NLRP1 inflammasome, especially with regard to the biochemical and structural aspects. Our research will aim to understand its response to various stress signals. By using advanced biochemical techniques and structural analysis methods, we aim to uncover the mechanisms of how different cellular stress conditions are integrated by the NLRP1 inflammasome. This work will improve our understanding of the biology of the inflammasome and may identify potential therapeutic targets for inflammatory diseases.
